Search research articles
Contact Us
Filters
Showing results (171-180 of 436) with videos related to
Page
of 44
Sort By:
JAMA Internal Medicine
|
October 5, 2017
Strategies That Delay Market Entry of Generic Drugs
Kerstin Noëlle Vokinger, Aaron S Kesselheim, Jerry Avorn, et al.
Health Affairs (Project Hope)
|
January 20, 2017
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers
Aaron S Kesselheim, Benjamin N Rome, Ameet Sarpatwari, et al.
The Annals of Pharmacotherapy
|
January 26, 2012
Comment: generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies
Joshua J Gagne, Jerry Avorn, William H Shrank, et al.
BMJ (Clinical Research Ed.)
|
August 20, 2024
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, et al.
The New England Journal of Medicine
|
November 19, 2004
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
Michael A Fischer, Sebastian Schneeweiss, Jerry Avorn, et al.
Health Services Research
|
September 13, 2003
Improved comorbidity adjustment for predicting mortality in Medicare populations
Sebastian Schneeweiss, Philip S Wang, Jerry Avorn, et al.
Archives of Internal Medicine
|
May 22, 2002
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction
Daniel H Solomon, Robert J Glynn, Raisa Levin, et al.
Plos Medicine
|
March 18, 2015
Paying physicians to prescribe generic drugs and follow-on biologics in the United States
Ameet Sarpatwari, Niteesh K Choudhry, Jerry Avorn, et al.
JAMA Network Open
|
November 8, 2022
Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
Mike Z Zhai, Jerry Avorn, Jun Liu, et al.
Contraception
|
January 26, 2016
Trends in direct-to-consumer advertising of prescription contraceptives
Min H Wu, Deborah Bartz, Jerry Avorn, et al.
Page
of 44
Search research articles
Search
Showing results (171-180 of 436) with videos related to
Sort By:
Page
of 44
JAMA Internal Medicine
|
October 5, 2017
Strategies That Delay Market Entry of Generic Drugs
Kerstin Noëlle Vokinger, Aaron S Kesselheim, Jerry Avorn, et al.
Health Affairs (Project Hope)
|
January 20, 2017
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers
Aaron S Kesselheim, Benjamin N Rome, Ameet Sarpatwari, et al.
The Annals of Pharmacotherapy
|
January 26, 2012
Comment: generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies
Joshua J Gagne, Jerry Avorn, William H Shrank, et al.
BMJ (Clinical Research Ed.)
|
August 20, 2024
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, et al.
The New England Journal of Medicine
|
November 19, 2004
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
Michael A Fischer, Sebastian Schneeweiss, Jerry Avorn, et al.
Health Services Research
|
September 13, 2003
Improved comorbidity adjustment for predicting mortality in Medicare populations
Sebastian Schneeweiss, Philip S Wang, Jerry Avorn, et al.
Archives of Internal Medicine
|
May 22, 2002
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction
Daniel H Solomon, Robert J Glynn, Raisa Levin, et al.
Plos Medicine
|
March 18, 2015
Paying physicians to prescribe generic drugs and follow-on biologics in the United States
Ameet Sarpatwari, Niteesh K Choudhry, Jerry Avorn, et al.
JAMA Network Open
|
November 8, 2022
Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
Mike Z Zhai, Jerry Avorn, Jun Liu, et al.
Contraception
|
January 26, 2016
Trends in direct-to-consumer advertising of prescription contraceptives
Min H Wu, Deborah Bartz, Jerry Avorn, et al.
Page
of 44